- Data from a Phase II study of a Revlimid/ dexamethasone combo followed by Revlimid (CELG +1.6%) maintenance therapy in patients with high-risk asymptomatic smoldering multiple myeloma have been published in the August 1 edition of the New England Journal of Medicine.
- Primary endpoint results: At a median follow-up of 40 months, median time to progression was "significantly longer in the treatment group compared with the observation group." (PR, full article)